Image

Middle East and Africa Adalimumab Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Middle East and Africa Adalimumab Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • MEA
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Middle East and Africa Adalimumab Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 134.81 USD Million
Diagram Market Size (Forecast Year) USD 181.68 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Middle East and Africa Adalimumab Market, By Drug class (Antirheumatics, TNF Alfa Inhibitors, Others), Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Middle East and Africa Adalimumab Market

Market Analysis and Size

Adalimumab, which was first licensed in the United States, is now available in more than 60 countries. Its Middle East and Africa market is consolidated, with only a few firms attempting to outsmart one other on price. Most of the major players are currently concentrating their efforts on the development of adalimumab biosimilars for the treatment of rheumatoid arthritis and psoriasis. This is seen in clinical trials testing the safety and efficacy of adalimumab biosimilars in the treatment of medical disorders. Many inflammatory disorders in adults are treated with adalimumab, including ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa.

Data Bridge Market Research analyses that the Middle East and Africa adalimumab market was valued at USD 134.81 million in 2021 and is expected to reach USD 181.68 million by 2029, registering a CAGR of 3.80% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug class (Antirheumatics, TNF Alfa Inhibitors, Others), Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Market Players Covered

Mylan N.V. (US), AbbVie Inc. (US), Zydus Cadila (India), Pfizer Inc. (US), Hetero Biopharma Ltd. (India), Boehringer Ingelheim International GmbH. (Germany)

Market Opportunities

  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies

Market Definition

Adalimumab is a prescription medicine which is sold under the brand names Humira and Exemptia. heumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, and ulcerative colitis are all treated with adalimumab. TNF (tumour necrosis factor alpha) is commonly bound by adalimumab. When TNF interacts to TBF receptors, an inflammatory response to autoimmune illness is triggered. By binding to a TNF, adalimumab reduces the likelihood of an inflammatory response.

Middle East and Africa Adalimumab Market Dynamics

Drivers

  • Rise in the incidence rate of  autoimmune disease

The rise in incidences of autoimmune disease such as psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis and Crohn's disease is anticipated to flourish the growth rate of the market. Adalimumab is a medication that reduces pain and swelling while also slowing the progression of arthritis. Adalimumab is used to treat active enthesitis-related arthritis, Rheumatoid arthritis, osteoarthritis, polyarticular juvenile idiopathic arthritis and other autoimmune conditions. Along with this, the growing prevalence of chronic disorders will enhance the demand of adalimumab market.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of adalimumab market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Rising incidences of skin disorders

The incidences of skin disorders is estimated to propel the market’s growth rate during the forecast period of 2022-2029. The World Health Organization (WHO) estimates that 900 million people worldwide suffer from skin ailments at any given moment. TNF-alpha (tumor necrosis factor-alpha) is a critical participant in the inflammatory process that causes skin disorders including psoriasis. Adalimumab targets this protein in the body. Psoriasis is a skin condition that develops scaly red patches on the knees, elbows, trunk, and scalp. Psoriasis is caused by an overactive immune system response, which is suppressed by adalimumab. According to the National Psoriasis Foundation, 125 million individuals worldwide have psoriasis, accounting for 2 to 3 percent of the overall population, fueling market growth.

Furthermore, rising initiatives by public and private organizations to spread awareness and surging demand for biosimilar drugs owing to their cost-effectiveness will expand the adalimumab market. Additionally, surging number of geriatric population and rising cases of upper respiratory tract infection will result in the expansion of adalimumab market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the adalimumab market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the adalimumab market growth during the forecast period.

Restraints/Challenges

  • High cost as well as side effects associated with adalimumab

Adalimumab is quite expensive for persons in low and middle-income nations, costing roughly USD 2000-3000 each infusion. Furthermore, adalimumab's negative effects are expected to limit market expansion. Fever, swollen glands, night sweats, general sensation of unwell, joint and muscle pain, skin rash, easy bruising or bleeding, and others are some of the frequent adverse effects of adalimumab. Adalimumab can also cause a type of lymphoma that is fatal, as well as cancers of the liver, spleen, and bone marrow. This is most common in teenagers and young men with Crohn's disease or ulcerative colitis, which slows market growth.

On the other hand, the lack of healthcare infrastructure in developing economies and strict regulatory process linked with product approval of biosimilars will challenge the adalimumab market. Additionally, patent expiration of drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Middle East and Africa adalimumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa adalimumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Middle East and Africa adalimumab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Middle East and Africa Adalimumab Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a Middle East and Africa pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic had delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations have imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The adalimumab market was hampered by the supply chain slowness.

Recent Development

  • In October 2021, The U.S. Food and Drug Administration (FDA) had announced the approval of first interchangeable biosimilar product for the treatment of various inflammatory diseases. The biosimilar and interchangeable approval pathway was established to help patients with critical medical conditions gain access to more treatment options. Cyltezo is the first interchangeable monoclonal antibody and the second interchangeable biosimilar medicine authorized by the FDA.

Middle East and Africa Adalimumab Market Scope

The Middle East and Africa adalimumab market is segmented on the basis of drug class, type, indication, dosage form, dosage strength, drug type, route of administration, age group, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug class

  • Antirheumatics
  • TNF Alfa Inhibitors
  • Others

Indication

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Chronic Plaque Psoriasis
  • Crohn's Disease
  • Ulcerative Colitis
  • Psoriatic Arthritis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Non-Infectious Intermediate
  • Others

Type

Dosage Strength

  • 40mg/0.4mlg
  • 80mg/0.8mlg
  • 20mg/0.2mlg
  • 10mg/0.1mlg
  • Others

Drug Type

  • Branded
  • Generics

Route of Administration

  • Oral
  • Parenteral
  • Others

Dosage Form

  • Injection
  • Solution
  • Tablet
  • Others

Age Group

  • Pediatric
  • Adult
  • Geriatric

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Middle East and Africa Adalimumab Market Regional Analysis/Insights

The Middle East and Africa adalimumab market is analysed and market size insights and trends are provided by country, drug class, type, indication, dosage form, dosage strength, drug type, route of administration, age group, end-users and distribution channel as referenced above.

The countries covered in the Middle East and Africa adalimumab market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Saudi Arabia dominates the adalimumab market because of the growing number of research and development activities to overcome the burden of arthritis diseases in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Middle East and Africa Adalimumab Market Share Analysis

The Middle East and Africa adalimumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Middle East and Africa adalimumab market.

Some of the major players operating in the Middle East and Africa adalimumab market are:

  • Mylan N.V. (US)
  • Zydus Cadila (India)
  • Boehringer Ingelheim International GmbH. (Germany)
  • AbbVie Inc. (US)
  • Abbott (US)
  • Hetero Biopharma Ltd. (India)


SKU-

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 SAUDI ARABIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 SAUDI ARABIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 60 SAUDI ARABIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 SAUDI ARABIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 62 SAUDI ARABIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 63 SAUDI ARABIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 SAUDI ARABIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 SAUDI ARABIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 66 SAUDI ARABIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 67 SAUDI ARABIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 68 SOUTH AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 69 SOUTH AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 SOUTH AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 SOUTH AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 72 SOUTH AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 73 SOUTH AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 SOUTH AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 75 SOUTH AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 76 SOUTH AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 77 SOUTH AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 78 UAE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 79 UAE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 UAE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 UAE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 82 UAE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 83 UAE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 UAE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 85 UAE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 86 UAE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 UAE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 88 ISRAEL ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 89 ISRAEL ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 ISRAEL BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 ISRAEL ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 92 ISRAEL ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 93 ISRAEL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 94 ISRAEL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 95 ISRAEL ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 96 ISRAEL ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 97 ISRAEL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 98 KUWAIT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 99 KUWAIT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 KUWAITBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 KUWAIT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 102 KUWAIT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 103 KUWAIT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 104 KUWAIT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 105 KUWAIT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 106 KUWAIT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 107 KUWAIT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 108 EGYPT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 109 EGYPT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 EGYPT BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 EGYPT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 112 EGYPT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 113 EGYPT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 114 EGYPT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 115 EGYPT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 116 EGYPT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 117 EGYPT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 118 REST OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

 

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

Middle East and Africa Adalimumab Market registering a CAGR of 3.80% by 2029.
Middle East and Africa Adalimumab Market is expected to reach USD 181.68 million by 2029.
The major players operating in the Middle East and Africa adalimumab market are: Mylan N.V. (US) Zydus Cadila (India) Boehringer Ingelheim International GmbH. (Germany) AbbVie Inc. (US) Abbott (US) Hetero Biopharma Ltd. (India).
Saudi Arabia dominates the adalimumab market because of the growing number of research and development activities to overcome the burden of arthritis diseases in this region.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials